Menopause Tech & devices Investment & deals

Therabody acquires Embr Labs technology to expand menopause innovation

By Published On: November 19, 2026
Therabody acquires Embr Labs technology to expand menopause innovation

Therabody has acquired Embr Labs’ thermal technology portfolio to support the development of future menopause products, including devices for managing hot flushes.

The acquisition covers the intellectual property behind the Embr Wave, a wrist-worn device that uses targeted cooling and warming to help manage hot flushes and improve sleep.

Therabody said the acquisition would support its work in women’s health, particularly products addressing symptoms associated with perimenopause and menopause.

Dr Rachelle Reed, head of scientific research and communication at Therabody, said: “Women make up half of the population, so supporting their health and well-being through every stage of life is a clear priority for us.”

The Embr Wave applies controlled temperature changes to the inside of the wrist, an area with a high concentration of temperature-sensitive nerves.

Research has examined whether the technology can help women manage menopausal symptoms.

In one randomised crossover study, two-thirds of women experiencing hot flushes reported improved thermal comfort and an increased ability to fall back asleep after waking during the night.

A crossover study involves participants receiving different treatments at separate stages so researchers can compare their effects.

Research published in 2025 also investigated whether artificial intelligence could predict hot flushes before women experienced them.

Researchers from Embr Labs and the University of Massachusetts Amherst developed an AI model that identified 82 per cent of menopausal hot flushes an average of 17 seconds before women felt them.

The findings suggest wearable devices could eventually deliver cooling before a hot flush begins, although this approach remains under development.

Matt Smith, co-founder and chief technology officer of Embr Labs, said: “We are thrilled that Therabody will carry our next-generation temperature technology forward.

“From developing the original Embr Wave to pioneering AI-driven hot flash prediction, our goal has always been about one thing: delivering real, immediate relief to the people who need it most.

“Therabody stands at the forefront of combining rigorous science with advanced technology, and their vision for the future of wellness aligns perfectly with our own.”

Hot flushes and night sweats affect up to three in four women during the menopause transition, according to research cited by the companies.

These symptoms, known as vasomotor symptoms, involve sudden sensations of heat and sweating associated with changes in the body’s temperature regulation.

Therabody has funded women’s health research since 2022, committing more than US$1m.

Its work includes studies on pain among postmenopausal women with the University of Michigan and research involving Black female runners with Georgia State University.

In 2025, the company launched Therabody for Her, an initiative focused on women’s health. Its scientists also completed a review of temperature regulation during menopause.

She said the company would continue Embr’s approach to research as it developed the technology further.

Founded at MIT, Embr Labs has developed temperature-based technology for managing thermal discomfort, hot flushes, sleep difficulties and stress.

Therabody said its engineering, research, manufacturing and distribution capabilities would support further development.

The company has not announced specific new products or launch dates resulting from the acquisition.

Existing Embr Wave 2 customers should continue contacting Embr Labs directly for orders and product support.

Report highlights progress in menstrual health awareness but persistent gaps in diagnosis
Post